News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,216 Results
Type
Article (41324)
Company Profile (265)
Press Release (687610)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204877)
Career Advice (2030)
Deals (35579)
Drug Delivery (128)
Drug Development (81540)
Employer Resources (173)
FDA (16502)
Job Trends (14979)
News (346872)
Policy (32761)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (45)
Adcomms (26)
Allergies (169)
Alliances (49607)
ALS (205)
Alzheimer's disease (1773)
Antibody-drug conjugate (ADC) (429)
Approvals (16870)
Artificial intelligence (637)
Autoimmune disease (262)
Automation (52)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (218)
Biotechnology (175)
Bladder cancer (184)
Brain cancer (70)
Breast cancer (731)
Cancer (5678)
Cardiovascular disease (455)
Career advice (1721)
Career pathing (41)
CAR-T (318)
CDC (55)
Celiac Disease (3)
Cell therapy (852)
Cervical cancer (46)
Clinical research (70638)
Collaboration (2009)
Company closure (5)
Compensation (1347)
Complete response letters (77)
COVID-19 (2734)
CRISPR (104)
C-suite (1077)
Cystic fibrosis (150)
Data (7577)
Decentralized trials (3)
Denatured (27)
Depression (157)
Dermatology (78)
Diabetes (578)
Diagnostics (6896)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (310)
Drug pricing (199)
Drug shortages (31)
Duchenne muscular dystrophy (274)
Earnings (91484)
Editorial (65)
Employer branding (21)
Employer resources (152)
Events (119102)
Executive appointments (1064)
FDA (20129)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1682)
Gene editing (225)
Generative AI (54)
Gene therapy (688)
GLP-1 (1038)
Government (4717)
Grass and pollen (6)
Guidances (403)
Healthcare (18972)
HIV (77)
Huntington's disease (56)
IgA nephropathy (93)
Immunology and inflammation (286)
Immuno-oncology (86)
Indications (176)
Infectious disease (3068)
Inflammatory bowel disease (208)
Inflation Reduction Act (14)
Influenza (135)
Intellectual property (286)
Interviews (318)
IPO (16660)
IRA (50)
Job creations (3648)
Job search strategy (1430)
JPM (58)
Kidney cancer (18)
Labor market (96)
Layoffs (559)
Leadership (37)
Legal (7955)
Liver cancer (99)
Longevity (32)
Lung cancer (752)
Lymphoma (421)
Machine learning (59)
Management (59)
Manufacturing (1000)
MASH (179)
Medical device (13903)
Medtech (14005)
Mergers & acquisitions (20144)
Metabolic disorders (1466)
mRNA (195)
Multiple sclerosis (184)
NASH (17)
Neurodegenerative disease (407)
Neuropsychiatric disorders (104)
Neuroscience (3250)
Neurotech (1)
NextGen: Class of 2026 (6522)
Non-profit (4529)
Now hiring (76)
Obesity (686)
Opinion (286)
Ovarian cancer (209)
Pain (247)
Pancreatic cancer (291)
Parkinson's disease (352)
Partnered (33)
Patents (583)
Patient recruitment (644)
Peanut (61)
People (59487)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22014)
Phase 2 (31113)
Phase 3 (23164)
Pipeline (7983)
Policy (309)
Postmarket research (2574)
Preclinical (9371)
Press Release (64)
Prostate cancer (291)
Psychedelics (52)
Radiopharmaceuticals (317)
Rare diseases (1038)
Real estate (5966)
Recruiting (70)
Regulatory (25292)
Reports (55)
Research institute (2411)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (176)
Series A (282)
Series B (207)
Service/supplier (11)
Sickle cell disease (109)
Special edition (22)
Spinal muscular atrophy (166)
Sponsored (47)
Startups (3636)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1081)
Venture capital (103)
Weight loss (441)
Women's health (121)
Worklife (20)
Date
Today (170)
Last 7 days (823)
Last 30 days (2795)
Last 365 days (30203)
2026 (10771)
2025 (30176)
2024 (35220)
2023 (40076)
2022 (51178)
2021 (55709)
2020 (54088)
2019 (46541)
2018 (35020)
2017 (32110)
2016 (31483)
2015 (37561)
2014 (31322)
2013 (26357)
2012 (28577)
2011 (29273)
2010 (27334)
Location
Africa (740)
Alabama (91)
Alaska (7)
Arizona (343)
Arkansas (14)
Asia (39612)
Australia (6491)
California (12857)
Canada (3676)
China (1298)
Colorado (547)
Connecticut (556)
Delaware (392)
Europe (85750)
Florida (1929)
Georgia (412)
Hawaii (3)
Idaho (62)
Illinois (1026)
India (88)
Indiana (586)
Iowa (23)
Japan (517)
Kansas (129)
Kentucky (50)
Louisiana (39)
Maine (75)
Maryland (1547)
Massachusetts (9150)
Michigan (355)
Minnesota (696)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (138)
New Hampshire (84)
New Jersey (3399)
New Mexico (28)
New York (3372)
North Carolina (1629)
North Dakota (8)
Northern California (6412)
Ohio (382)
Oklahoma (23)
Oregon (41)
Pennsylvania (2588)
Puerto Rico (28)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5068)
Tennessee (207)
Texas (2032)
United States (45403)
Utah (383)
Vermont (1)
Virginia (307)
Washington D.C. (80)
Washington State (1033)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
729,216 Results for "ucb inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
UCB elevates epilepsy expertise with up to $1.15B Neurona takeover
The acquisition of Neurona will put UCB in both the epilepsy and cell therapy space, even as many of its fellow pharmas move away from the latter modality.
April 20, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
UCB captures Candid in $2.2B autoimmune deal as pharma’s M&A train chugs along
Candid Therapeutics follows closely behind Neurona Therapeutics, which UCB acquired in mid-April in a potential $1.15 billion deal.
May 4, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
UCB Investing $2B To Build Manufacturing Facility in Georgia
The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S.
March 25, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers
May 4, 2026
·
9 min read
Press Releases
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
April 19, 2026
·
10 min read
Press Releases
PANTHERx® Rare Selected by UCB as the Exclusive Specialty Pharmacy for the Distribution of KYGEVVI™
March 24, 2026
·
3 min read
Press Releases
UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
April 13, 2026
·
17 min read
Press Releases
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
March 25, 2026
·
9 min read
Press Releases
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
March 30, 2026
·
18 min read
Dermatology
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical and regulatory victories.
April 8, 2026
·
2 min read
·
Tristan Manalac
1 of 72,922
Next
